Biosketch Francesc Bosch

Francesc Bosch

fbosch@vhio.net

Puesto actual

2016 – actualidad: Jefe de grupo, Grupo de Hematología Experimental del VHIO
10/2010 – actualidad: Profesor del Departamento de Medicina de la Universidad Autónoma de Barcelona, España
09/2009 – actualidad: Jefe del Departamento de Hematología del Hospital Universitario Vall d’Hebron (HUVH), Barcelona, España

Formación académica

09/1992 – 09/1993: Universidad Autónoma de Barcelona, España
Análisis multivariable en ciencias de la salud
09/1993 – 09/1994: Universidad Autónoma de Barcelona, España
Fundamentos del diseño y la estadística (médicos)
09/1982 – 10/1988: Universidad de Barcelona, España
Licenciatura en Medicina y Postgrado en Cirugía
10/1988 – 12/1992: Universidad de Barcelona, España
Certificado en Hematología del Consejo Español
07/1998: Universidad de Barcelona, España
Tesis doctoral: “El gen de la ciclina D1 en los trastornos linfoproliferativos crónicos”
Premio Extraordinario de Doctorado

Áreas de investigación

Estudios biológicos y clínicos en neoplasias hematológicas.

Premios y becas

Premios

07/1998: Premio Extraordinario de Doctorado
1996: Premio para Jóvenes Investigadores, París. Sociedad Europea de Hematología
1994: Premio para Jóvenes Investigadores. Sociedad Catalana de Hematología
2018: Premio Best in Class (BiC) a la mejor unidad de CLL.
2014: Premio a la Excelencia Profesional. Colegio Oficial de Médicos de Barcelona

Honores

07/2009: Coordinadora del Grupo Español de CLL
2007: Principal organizadora del Grupo de Jóvenes Investigadores sobre LLC
1996: Miembro del Proyecto Europeo para el Linfoma de Células del Manto
1996: Miembro fundadora del Grupo de Estudio de los Linfomas en Cataluña y Baleares (GELCAB)

Becas

01/1998 – 12/2000: Instituto de Genética del Cáncer, Universidad de Columbia, Nueva York, EE. UU. Investigadora postdoctoral
09/2017 – 09/2018: Instituto de Genética del Cáncer, Universidad de Columbia, Nueva York, EE. UU. Investigadora postdoctoral

Proyectos

Project title: Exploración y prueba de concepto de la eficacia del tratamiento combinado con Ory-1001 en indicaciones oncológicas (COMBO-EPoC).
Duration: 01/01/2018 – 31/03/2021.
Funding entity: MINECO-RETOS
PI: Francesc Bosch.
Project title: Uso de linfocitos T específicos third partycontra antígenos virales, procedentes de un registro de donantes voluntarios, para el tratamiento de infecciones por CMV, VEB y adenovirus.
Duration: 01/01/2017 – 30/06/2021.
Funding entity: FIS-ISCIII.
PI: Pere Barba.
Project title: Estudio funcional del sistema inmune (SI) en síndromes mielodisplásicos (SMD) según el perfil mutacional. Influencia de las alteraciones evolutivas del SI en la progresión del SMD.
Duration: 01/01/2018 – 01/07/2021.
Funding entity: FIS-ISCIII.
PI: David Valcarcel
Project title: Patogénesis y nuevas dianas moleculares en sindromes linfoproliferativos.
Duration: 01/12/2013 – 31/12/2021.
Funding entity: MINECO-RyC (MINECO Ramón y Cajal).
PI: Marta Crespo.
Project title: Papel de la vigilancia y evasión inmune en la fisiopatología y inmunoterapia de los linfomas del sistema nervioso central.
Duration: 01/01/2018 – 01/01/2022.
Funding entity: FIS-ISCIII.
PI: Marta Crespo.
Project title: Optimización del uso de inhibidores de checkpoint en pacientes con neoplasias linfoides que reciben un trasplante alogénico de progenitores hematopoyético.
Duration: 01/08/2019 – 01/03/2022.
Funding entity: Fundación Científica de la Asociación Española Contra el Cáncer.
PI: Pere Barba.
Project title: Macrophage-mediated immunotherapy optimization in lymphomas affecting the central nervous system.
Duration: 01/11/2018 – 31/10/2022.
Funding entity: Fundación Científica de la Asociación Española Contra el Cáncer.
PI: Marta Crespo.
Project title: Predicción de la respuesta a lusparceptept en los síndromes mielodiplásicos: análisis de la diferenciación eritroide terminal mediante un sist. ex vivo y RNA seq.
Duration: 01/03/2018 – 31/12/2022.
Funding entity: Fundación Española de Hematología y Hemoterapía.
PI: Francesc Bosch.
Project title: Inhibición de la proteína quinasa ZAP-70 como terapia dirigida en linfomas T periféricos.
Duration: 01/01/2019 – 31/12/2022.
Funding entity: FIS-ISCIII.
PI: Pau Abrisqueta.
Project title: Estudi i implicacions translacionals de l’evasió del sistema immunitari en la leucèmia limfàtica crónica.
Duration: 01/06/2020 – 12/07/2023.
Funding entity: MARATÓ TV3.
PI: Francesc Bosch.
Project title: Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos
Duration: 01/06/2019 – 31/12/2023.
PI: David Valcarcel.

Publicaciones científicas más relevantes

Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, Yáñez L, Quintanilla-Martínez L, Bosch F. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023 Nov;120:102619.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Am J Hematol. 2023 Aug;98(8):1204-1213.
Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. EJHaem. 2023 Sep 11;4(4):1081-1088.
Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, Yáñez L, Quintanilla-Martínez L, Bosch F. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023 Nov;120:102619.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Am J Hematol. 2023 Aug;98(8):1204-1213.
Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. EJHaem. 2023 Sep 11;4(4):1081-1088.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023 Jul 29;402(10399):373-385.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023 Jan 28;401(10373):269-280.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Apthorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D’Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, Patriarca A, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D’Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. Lancet Oncol. 2023 Apr;24(4):335-346.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol. 2023 Jun 1;41(16):3019-3031.
Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discov. 2023 Sep 6;13(9):1982-1997.
Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023 Sep;10(9):e735-e746.
Iacoboni G, Dietrich S, Liebers N. CAR T-cell therapy versus allogeneic HSCT for relapsed or refractory mantle cell lymphoma. Lancet Haematol. 2023 Dec;10(12):e951-e952.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jäger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sánchez-Guijo F, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden JA, Thieblemont C, Topp M, Zinzani PL, Gribben JG, Bonini C, Sureda A, Yakoub-Agha I. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023 Sep 7;142(10):865-877.
de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood. 2023 Jan 12;141(2):156-167.
Moreno V, Vieito M, Sepulveda JM, Galvao V, Hernández-Guerrero T, Doger B, Saavedra O, Carlo-Stella C, Michot JM, Italiano A, Magagnoli M, Carpio C, Pinto A, Sarmiento R, Amoroso B, Aronchik I, Filvaroff E, Hanna B, Wei X, Nikolova Z, Braña I. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas. Nat Commun. 2023 Mar 13;14(1):1359.
Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA, Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson D, Santos GD, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Fresa A, Galimberti S, Galitzia A, García-Serra R, Gimeno E, González-Gascón-Y-Marín I, Gozzetti A, Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Inchiappa L, Jaksic O, Janssen S, Kalicińska E, Kamel L, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren-Michowitz M, Kotsianidis I, Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez-Garcia A, Marquet J, Martin-Rodríguez L, Maynadié M, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro-Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska-Stavridis I, Papaioannou M, Papajík T, Kubova Z, Phumphukhieo P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin GM, Ruchlemer R, Daniel de Deus Santos M, Schipani M, Schiwitza A, Shen Y, Simkovic M, Smirnova S, Abdelrahman Soliman DS, Spacek M, Tadmor T, Tomic K, Tse E, Vassilakopoulos T, Visentin A, Vitale C, von Tresckow J, Vrachiolias G, Vukovic V, Walewska R, Wasik-Szczepanek E, Xu Z, Yagci M, Yañez L, Yassin M, Zuchnicka J, Angelopoulou M, Antic D, Biderman B, Catherwood M, Claus R, Coscia M, Cuneo A, Demirkan F, Espinet B, Gaidano G, Kalashnikova OB, Laurenti L, Nikitin E, Pangalis GA, Panagiotidis P, Popov VM, Pospisilova S, Sportoletti P, Stavroyianni N, Tam C, Trentin L, Chatzidimitriou A, Bosch F, Doubek M, Ghia P, Stamatopoulos K. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine. 2023 Nov 15;65:102307.
Salmanton-García J, Marchesi F, Gomes da Silva M, Farina F, Dávila-Valls J, Bilgin YM, Glenthøj A, Falces-Romero I, Van Doesum J, Labrador J, Buquicchio C, El-Ashwah S, Petzer V, Van Praet J, Schönlein M, Dargenio M, Méndez GA, Meers S, Itri F, Giordano A, Pinczés LI, Espigado I, Stojanoski Z, López-García A, Prezioso L, Jaksic O, Vena A, Fracchiolla NS, González-López TJ, Colović N, Delia M, Weinbergerová B, Marchetti M, Marques de Almeida J, Finizio O, Besson C, Biernat MM, Valković T, Lahmer T, Cuccaro A, Ormazabal-Vélez I, Batinić J, Fernández N, De Jonge N, Tascini C, Anastasopoulou AN, Duléry R, Del Principe MI, Plantefeve G, Papa MV, Nucci M, Jiménez M, Aujayeb A, Hernández-Rivas JÁ, Merelli M, Cattaneo C, Blennow O, Nordlander A, Cabirta A, Varricchio G, Sacchi MV, Cordoba R, Arellano E, Gräfe SK, Wolf D, Emarah Z, Ammatuna E, Hersby DS, Martín-Pérez S, Nunes Rodrigues R, Rahimli L, Pagano L, Cornely OA; EPICOVIDEHA registry. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. EClinicalMedicine. 2023 Apr;58:101939.
Andrés C, González-Sánchez A, Jiménez M, Márquez-Algaba E, Piñana M, Fernández-Naval C, Esperalba J, Saubi N, Quer J, Rando-Segura A, Miarons M, Codina MG, Ruiz-Camps I, Pumarola T, Abrisqueta P, Antón A. Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion. Clin Microbiol Infect. 2023 Feb;29(2):240-246.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep 22;9(38):eadg3919.
Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bücklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov;98(11):1699-1710.
Jiménez M, Fernández-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, Andrés C, Antón A, Peralta S, Pujadas G, Hernández C, Pagès C, Roldán E, Pumarola T, Gironella M, Ruiz-Camps I, Martínez-Gómez X, Valcárcel D, Hernández M, Bosch F, Crespo M, Esperalba J, Abrisqueta P. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms. Am J Hematol. 2023 Aug;98(8):1204-1213.
Ortí G, Gras L, Zinger N, Finazzi MC, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, Radujkovic A, Hunault-Berger M, Schroyens W, Zuckerman T, Bourhis JH, Chalandon Y, Bloor A, Schots R, de Wreede LC, Drozd-Sokolowska J, Raj K, Polverelli N, Czerw T, Hernández-Boluda JC, McLornan D, Yakoub-Agha I. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023 Apr;98(4):628-638.
Oñate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Avila SG, Bargay J, Ortín X, Nomdedéu JF, Esteve J, Sierra J; Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM). Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J. 2023 May 5;13(1):69.
de la Asunción CS, Giménez E, Hernández-Boluda JC, Terol MJ, Albert E, López J, García-Gutiérrez V, Andreu R, Malo MDG, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study. J Med Virol. 2023 Jul;95(7):e28933.
Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, Yáñez L, Quintanilla-Martínez L, Bosch F. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023 Nov;120:102619.
Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoz MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023 Feb;37(2):339-347.
Marin-Bejar O, Romero-Moya D, Rodriguez-Ubreva J, Distefano M, Lessi F, Aretini P, Liquori A, Castaño J, Kozyra E, Kotmayer L, Bueno C, Cervera J, Rodriguez-Gallego JC, Nomdedeu JF, Murillo-Sanjuán L, De Heredia CD, Pérez-Martinez A, López-Cadenas F, Martínez-Laperche C, Dorado-Herrero N, Marco FM, Prósper F, Menendez P, Valcárcel D, Ballestar E, Bödör C, Bigas A, Catalá A, Wlodarski MW, Giorgetti A. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency. Haematologica. 2023 Sep 1;108(9):2551-2557.
Murthy GSG, Kim S, Estrada-Merly N, Abid MB, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Cerny J, Chhabra S, DeFilipp Z, Dholaria B, Perez MAD, Farhan S, Freytes CO, Gale RP, Ganguly S, Gupta V, Grunwald MR, Hamad N, Hildebrandt GC, Inamoto Y, Jain T, Jamy O, Juckett M, Kalaycio M, Krem MM, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Ortí G, Patel SS, Van der Poel M, Rizzieri DA, Savani BN, Seo S, Solh M, Verdonck LF, Wirk B, Yared JA, Nakamura R, Oran B, Scott B, Saber W. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 1;108(7):1900-1908.
González-Gil C, Morgades M, Lopes T, Fuster-Tormo F, García-Chica J, Zhao R, Montesinos P, Torrent A, Diaz-Beya M, Coll R, Hermosín L, Mercadal S, González-Campos J, Zamora L, Artola T, Vall-Llovera F, Tormo M, Gil-Cortés C, Barba P, Novo A, Ribera J, Bernal T, De Ugarriza PL, Queipo MP, Martínez-Sánchez P, Giménez A, González-Martínez T, Cladera A, Cervera J, Fernández-Martín R, Ardaiz MÁ, Vidal MJ, Baena Á, López-Bigas N, Bigas A, Maciejewski J, Orfao A, Ribera JM, Genescà E. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials. Haematologica. 2023 Apr 1;108(4):969-980.
Bobillo S, Khwaja J, Ferreri AJM, Cwynarski K. Prevention and management of secondary central nervous system lymphoma. Haematologica. 2023 Mar 1;108(3):673-689.
Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Ráčil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux MP, Verga L, Weinbergerová B, Szotkovski T, Da Silva MG, Fracchiolla N, De Jonge N, Collins G, Marchetti M, Magliano G, García-Vidal C, Biernat MM, Van Doesum J, Machado M, Demirkan F, Al-Khabori M, Žák P, Víšek B, Stoma I, Méndez GA, Maertens J, Khanna N, Espigado I, Dragonetti G, Fianchi L, Del Principe MI, Cabirta A, Ormazabal-Vélez I, Jaksic O, Buquicchio C, Bonuomo V, Batinić J, Omrani AS, Lamure S, Finizio O, Fernández N, Falces-Romero I, Blennow O, Bergantim R, Ali N, Win S, Van Praet J, Tisi MC, Shirinova A, Schönlein M, Prattes J, Piedimonte M, Petzer V, Navrátil M, Kulasekararaj A, Jindra P, Sramek J, Glenthøj A, Fazzi R, De Ramón-Sánchez C, Cattaneo C, Calbacho M, Bahr NC, El-Ashwah S, Cordoba R, Hanakova M, Zambrotta G, Sciumè M, Booth S, Rodrigues RN, Sacchi MV, García-Poutón N, Martín-González JA, Khostelidi S, Gräfe S, Rahimli L, Ammatuna E, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely OA, Pagano L; EPICOVIDEHA working group. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica. 2023 Jan 1;108(1):22-33.
Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Domínguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bailén R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebrián NM, Martin JLD, Martín A, Barba P. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023 Jan 1;108(1):110-121.
Ghione P, Palomba ML, Ghesquieres H, Bobillo S, Patel AR, Nahas M, Kanters S, Deighton K, Hatswell A, Ma L, Limbrick-Oldfield EH, Snider JT, Wade SW, Riberio MT, Radford J, Beygi S, Gribben J. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023 Mar 1;108(3):822-832.
Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study. Hemasphere. 2023 Oct 24;7(11):e966.
Alvarez-Larrán A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marín F, Carbonell S, Pérez-Encinas M, Gómez-Casares MT, Pérez-López R, Magro E, Moretó A, Pastor-Galán I, Angona A, Mata-Vázquez MI, Guerrero-Fernández L, Guerra JM, Carreño-Tarragona G, Fox L, Murillo I, García-Gutiérrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernández-Boluda JC, Pereira A. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia. Hemasphere. 2023 Jul 18;7(8):e936.
Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, Kharboutli S, Blumenberg V, Ackermann J, Frölich L, Johnson G, Patel K, Arciola B, Mhaskar R, Wood A, Schmidt C, Albanyan O, Gödel P, Hoster E, Bullinger L, Mackensen A, Locke F, von Bergwelt M, Barba P, Subklewe M, Jain MD. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. Hemasphere. 2023 Jul 11;7(8):e907.
Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, Petrera A, Müller N, Hildebrand F, Frölich L, Karschnia P, Schmidt C, Cordas Dos Santos DM, Piñana JL, Müller F, Martin AA, Dreyling M, von Bergwelt-Baildon M, Barba P, Subklewe M, Bücklein VL. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. Hemasphere. 2023 Apr 5;7(4):e858.
Collado A, Boaro MP, van der Veen S, Idrizovic A, Biemond BJ, Beneitez Pastor D, Ortuño A, Cela E, Ruiz-Llobet A, Bartolucci P, de Montalembert M, Castellani G, Biondi R, Manara R, Sanavia T, Fariselli P, Kountouris P, Kleanthous M, Alvarez F, Zazo S, Colombatti R, van Beers EJ, Mañú-Pereira MDM. Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet. Hemasphere. 2023 Feb 22;7(3):e844.
Mosquera Orgueira A, Perez Encinas MM, Diaz Varela NA, Mora E, Díaz-Beyá M, Montoro MJ, Pomares H, Ramos F, Tormo M, Jerez A, Nomdedeu JF, De Miguel Sanchez C, Leonor A, Cárcel P, Cedena Romero MT, Xicoy B, Rivero E, Del Orbe Barreto RA, Diez-Campelo M, Benlloch LE, Crucitti D, Valcárcel D. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes. Hemasphere. 2023 Oct 11;7(10):e961.
Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, de Llano MPQ, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols. Hemasphere. 2022 Dec 23;7(1):e810.
Rossi G, Salmanton-García J, Cattaneo C, Marchesi F, Dávila-Valls J, Martín-Pérez S, Itri F, López-García A, Glenthøj A, Gomes da Silva M, Besson C, Marchetti M, Weinbergerová B, Jaksic O, Jiménez M, Bilgin YM, Van Doesum J, Farina F, Žák P, Verga L, Collins GP, Bonuomo V, Van Praet J, Nucci M, Meers S, Espigado I, Fracchiolla NS, Valković T, Poulsen CB, Čolović N, Dragonetti G, Ledoux MP, Tascini C, Buquicchio C, Blennow O, Passamonti F, Machado M, Labrador J, Duarte RF, Schönlein M, Prezioso L, Falces-Romero I, Kulasekararaj A, Garcia-Vidal C, Fernández N, Abu-Zeinah G, Ormazabal-Vélez I, Adžić-Vukičević T, Piukovics K, Stoma I, Cuccaro A, Magliano G, Szotkowski T, González-López TJ, El-Ashwah S, Bergantim R, Sili U, Maertens J, Demirkan F, De Ramón C, Petzer V, Del Principe MI, Navrátil M, Dargenio M, Seval GC, Samarkos M, Ráčil Z, Pinczés LI, Lahmer T, Busca A, Méndez GA, Vena A, Biernat MM, Merelli M, Calbacho M, Barać A, Bavastro M, Limongelli A, Ilhan O, Wolf D, Çolak GM, García-Sanz R, Emarah Z, Mišković B, Gräfe SK, Mladenović M, Aiello TF, Núñez-Martín-Buitrago L, Nordlander A, Arellano E, Zambrotta GPM, Ammatuna E, Cabirta A, Sacchi MV, Nunes Rodrigues R, Hersby DS, Hanakova M, Rahimli L, Cordoba R, Cornely OA, Pagano L; Collaborators. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings. Int J Infect Dis. 2023 Dec;137:98-110.
Ainciburu M, Ezponda T, Berastegui N, Alfonso-Pierola A, Vilas-Zornoza A, San Martin-Uriz P, Alignani D, Lamo-Espinosa J, San-Julian M, Jiménez-Solas T, Lopez F, Muntion S, Sanchez-Guijo F, Molero A, Montoro J, Serrano G, Diaz-Mazkiaran A, Lasaga M, Gomez-Cabrero D, Diez-Campelo M, Valcarcel D, Hernaez M, Romero JP, Prosper F. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution. Elife. 2023 Jan 11;12:e79363.
Blumenberg V, Busch G, Baumann S, Jitschin R, Iacoboni G, Gallur L, Iraola-Truchuelo J, Hoster E, Winkelmann M, Hellwig K, Schmidt C, Frölich L, Tast B, Hildebrand F, Rejeski K, Dekorsy F, Schmidkonz C, Bäuerle T, Kunz WG, Mougiakakos D, Müller F, von Bergwelt-Baildon M, Barba P, Bücklein VL, Mackensen A, Völkl S, Subklewe M. Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL. Blood Adv. 2023 Nov 28;7(22):6844-6849.
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023 Sep 12;7(17):4926-4935.
van Doesum JA, Salmanton-García J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, Farina F, Besson C, Weinbergerová B, Van Praet J, Schönlein M, López-García A, Lamure S, Guidetti A, De Ramón-Sánchez C, Batinić J, Gavriilaki E, Tragiannidis A, Tisi MC, Plantefeve G, Petzer V, Ormazabal-Vélez I, Marques de Almeida J, Marchetti M, Maertens J, Machado M, Kulasekararaj A, Hernández-Rivas JÁ, Gomes da Silva M, Fernández N, Espigado I, Drgoňa Ľ, Dragonetti G, Metafuni E, Calbacho M, Blennow O, Wolf D, van Anrooij B, Nunes Rodrigues R, Nordlander A, Martín-González JA, Liévin R, Jiménez M, Gräfe SK, García-Sanz R, Córdoba R, Rahimli L, van Meerten T, Cornely OA, Pagano L. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023 Jun 13;7(11):2645-2655.
Ribeiro ML, Profitós-Pelejà N, Santos JC, Blecua P, Reyes-Garau D, Armengol M, Fernández-Serrano M, Miskin HP, Bosch F, Esteller M, Normant E, Roué G. G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy. Front Immunol. 2023 Apr 21;14:1130052.
Busca A, Salmanton-García J, Marchesi F, Farina F, Seval GC, Van Doesum J, De Jonge N, Bahr NC, Maertens J, Meletiadis J, Fracchiolla NS, Weinbergerová B, Verga L, Ráčil Z, Jiménez M, Glenthøj A, Blennow O, Tanase AD, Schönlein M, Prezioso L, Khanna N, Duarte RF, Žák P, Nucci M, Machado M, Kulasekararaj A, Espigado I, De Kort E, Ribera-Santa Susana JM, Marchetti M, Magliano G, Falces-Romero I, Ilhan O, Ammatuna E, Zompi S, Tsirigotis P, Antoniadou A, Zambrotta GPM, Nordlander A, Karlsson LK, Hanakova M, Dragonetti G, Cabirta A, Berg Venemyr C, Gräfe S, Van Praet J, Tragiannidis A, Petzer V, López-García A, Itri F, Groh A, Gavriilaki E, Dargenio M, Rahimli L, Cornely OA, Pagano L. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry. Front Immunol. 2023 Feb 24;14:1125030.
Muntañola A, Villalobos MT, González-Villambrosia S, Rodríguez-Salazar MJ, Jiménez-Ubieto A, Bastidas-Mora G, Córdoba R, Infante M, Vidal MJ, Díaz FJ, Baile M, Bastos-Oreiro M, Panizo C, Sancho JM, Navarro B, García T, Escoda L, Abrisqueta P, Terol MJ, de Campo R, Mozas P, López-Guillermo A, Salar A, Montalbán C; GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study. Br J Haematol. 2023 Aug;202(4):776-784.
Simoes C, Villar S, Ariceta B, Garcés JJ, Burgos L, Alignani D, Sarvide S, Martínez-Cuadrón D, Bergua JM, Vives S, Algarra L, Tormo M, Martinez P, Serrano J, Herrera P, Ramos F, Salamero O, Lavilla E, Gil C, Lopez-Lorenzo JL, Vidriales MB, Chillon C, Labrador J, Falantes JF, Sayas MJ, Ayala R, Martinez-Lopez J, Pierola AA, Calasanz MJ, Prosper F, San-Miguel JF, Sanz MÁ, Paiva B, Montesinos P; PETHEMA cooperative study group. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. Br J Haematol. 2023 Jun;201(6):1239-1244.
de la Asunción Carlos S, Giménez E, Hernández-Boluda JC, Terol MJ, Albert E, López-Jiménez J, García-Gutiérrez V, Andreu R, García D, Fox ML, Remigia MJ, Amat P, Solano C, Navarro D. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors. Br J Haematol. 2023 Mar;200(6):e58-e61.
Muntañola A, Mozas P, Mercadal S, Huguet M, Bobillo S, Bastos-Oreiro M, Jiménez-Ubieto A, Rovira J, Rivero A, Tolosa C, Luizaga L, de Villambrosia SG, Novelli S, Caballero D, Salar A, Alonso-Álvarez S, Magnano L, Gutiérrez NC, Sancho JM, López-Guillermo A; GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br J Haematol. 2023 Feb;200(3):306-314.
Musri MM, Venturi V, Ferrer-Cortès X, Romero-Cortadellas L, Hernández G, Leoz P, Ricard Andrés MP, Morado M, Fernández Valle MDC, Beneitez Pastor D, Ortuño Cabrero A, Moreno Gamiz M, Senent Peris L, Perez-Valencia AI, Pérez-Montero S, Tornador C, Sánchez M. New Cases and Mutations in SEC23B Gene Causing Congenital Dyserythropoietic Anemia Type II. Int J Mol Sci. 2023 Jun 9;24(12):9935.
Clavero E, Sanchez-Maldonado JM, Macauda A, Ter Horst R, Sampaio-Marques B, Jurczyszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, García-Sanz R, Tomczak W, Vogel U, Jerez A, Zawirska D, Wątek M, Hofmann JN, Landi S, Spinelli JJ, Butrym A, Kumar A, Martínez-López J, Galimberti S, Sarasquete ME, Subocz E, Iskierka-Jażdżewska E, Giles GG, Rybicka-Ramos M, Kruszewski M, Abildgaard N, Verdejo FG, Sánchez Rovira P, da Silva Filho MI, Kadar K, Razny M, Cozen W, Pelosini M, Jurado M, Bhatti P, Dudzinski M, Druzd-Sitek A, Orciuolo E, Li Y, Norman AD, Zaucha JM, Reis RM, Markiewicz M, Rodríguez Sevilla JJ, Andersen V, Jamroziak K, Hemminki K, Berndt SI, Rajkumar V, Mazur G, Kumar SK, Ludovico P, Nagler A, Chanock SJ, Dumontet C, Machiela MJ, Varkonyi J, Camp NJ, Ziv E, Vangsted AJ, Brown EE, Campa D, Vachon CM, Netea MG, Canzian F, Försti A, Sainz J. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization. Int J Mol Sci. 2023 May 9;24(10):8500.
Cabrera-Serrano AJ, Sánchez-Maldonado JM, Ter Horst R, Macauda A, García-Martín P, Benavente Y, Landi S, Clay-Gilmour A, Niazi Y, Espinet B, Rodríguez-Sevilla JJ, Pérez EM, Maffei R, Blanco G, Giaccherini M, Cerhan JR, Marasca R, López-Nevot MÁ, Chen-Liang T, Thomsen H, Gámez I, Campa D, Moreno V, de Sanjosé S, Marcos-Gragera R, García-Álvarez M, Dierssen-Sotos T, Jerez A, Butrym A, Norman AD, Luppi M, Slager SL, Hemminki K, Li Y, Berndt SI, Casabonne D, Alcoceba M, Puiggros A, Netea MG, Försti A, Canzian F, Sainz J. Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression? Int J Mol Sci. 2023 Apr 28;24(9):8005.
Sánchez-Maldonado JM, Cabrera-Serrano AJ, Chattopadhyay S, Campa D, Garrido MDP, Macauda A, Ter Horst R, Jerez A, Netea MG, Li Y, Hemminki K, Canzian F, Försti A, Sainz J. GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis. Int J Mol Sci. 2023 Mar 23;24(7):6029.
Pascual-Izquierdo C, Piñera Salmerón P, Temboury Ruiz F, Valcárcel Ferreiras D, Jiménez Hernández S, Salinas Argente R, Del Arco Galán C, de la Rubia Comos J. Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments – an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES). Emergencias. 2023 Feb;35(1):44-52.
Calvete O, Mestre J, Jerez A, Solé F. The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw. Cancers (Basel). 2023 Feb 26;15(5):1483.
Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA 3rd, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, Townsend W, Miao H, Proscurshim I, Wang S, Katyayan S, Yuan Y, Zhu J, Stumpo K, Shou Y, Carpio C, Bosch F. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 Jan 26;14:57-70.
Mussetti A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, Albo C, Bailen R, Barba P, Benzaquén A, Briones J, Caballero AC, Campos A, Español I, Ferra C, López SG, González Sierra PA, Guerra LM, Hernani R, Iacoboni G, Jiménez-Ubieto A, Kwon M, Corral LL, López-Godino O, Munoz MCM, Martínez-Cibrián N, Gómez JM, Pérez-Ortega L, Ortí G, Ortiz-Maldonado V, Pascual MJ, Perera M, Perez A, Reguera JL, Sanchez JM, Sanz J, Torrent A, Yáñez L, Varela R, Echechipia IC, Caballero D, Sureda A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplant. 2023 Jun;58(6):673-679.
Saccardi R, Putter H, Eikema DJ, Busto MP, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FA, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari AMS, Chabannon C, Corbacioglu S, Dolstra H, Duarte RF, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour RP, Poirel HA, Rintala T, Rizzo JD, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras DV, Wilcox L, de Wreede LC, Snowden JA. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023 Jun;58(6):659-666.
Terrades NR, Senin A, Azancot MA, Gironella M, Toapanta N, Bermejo S, Martin L, Caravaca-Fontán F, Cuellar C, Martínez-Lopez J, Rodríguez E, Bestard O, Soler MJ. Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view. Clin Kidney J. 2023 Feb 1;16(6):1014-1021.
Bernal T, Moreno AF, de LaIglesia A, Benavente C, García-Noblejas A, Belmonte DG, Riaza R, Salamero O, Foncillas MA, Roldán A, Concepción VN, González LL, Bergua Burgués JM, Lorente de Uña S, Rodríguez-Macías G, de la Fuente Burguera A, García Pérez MJ, López-Lorenzo JL, Martínez P, Aláez C, Callejas M, Martínez-Chamorro C, Roca JR, Barciela LA, Mena Durán AV, Gómez Correcha K, Lavilla Rubira E, Amigo ML, Vall-Llovera F, Garrido A, García-Fortes M, de Miguel Llorente D, Leonardo AA, Cervero C, Jordá RC, Pérez-Encinas MM, Zarzuela MP, Figuera A, Rad G, Martínez-Cuadrón D, Montesinos P. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry. Cancer Med. 2023 Jul;12(14):14892-14901.
Mesa RA, Hudgens S, Floden L, Harrison CN, Palmer J, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins A, Leahy MF, Deheshi S, Donahue R, Klencke BJ, Verstovsek S. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. Cancer Med. 2023 May;12(9):10612-10624.
Boyiadzis M, Desai P, Daskalakis N, Donnellan W, Ferrante L, Goldberg JD, Grunwald MR, Guttke C, Li X, Perez-Simon JA, Salamero O, Tucker T, Xu X, Yang J, Pemmaraju N, Alonso-Dominguez JM. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin Transl Sci. 2023 Mar;16(3):429-435.
Muntañola A, Arguiñano-Pérez JM, Dávila J, de Villambrosia SG, Carpio C, Jiménez-Ubieto A, Salar A; GELTAMO (Grupo español de linfomas y trasplante de médula ósea). Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting. Clin Transl Sci. 2023 Feb;16(2):305-312.
Martínez C, de Haro ME, Romero S, Gutiérrez A, Domingo-Domènech E, González-Rodríguez AP, Zeberio I, Martínez-Badas MP, Rodríguez-Izquierdo A, Carpio C, Bastos-Oreiro M, Hernández-Rivas JÁ, Vallansot R, Kelleher N, Díaz-Gálvez FJ, Torrado T, Pereira A, García-Sanz R; Grupo Español de Linfoma y Trasplante de Médula Ósea (GELTAMO) y Grupo Español de Trasplante (GETH). Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Ann Hematol. 2023 Feb;102(2):429-437.
Ortuzar A, Fox ML, Vera JA, Lorenzo Vizcaya Á, Marín Sánchez A, Llopis Calatayud I, Carbonell S, Álvarez-Larrán A, Mata Serna R, Marco Buades JE, Quiroz Cervantes K, Martínez Hellín Á, Blum Domínguez A, Caballero Navarro G, Cáceres Sansaloni A, Guerrero Fernández L, Muñoz Linares C, Gasior Kabat M, Pérez López R, Fernández Rodríguez Á, Martínez Bilbao C, Cobo Rodríguez MT, Díaz Á, Durán MA, Santaliestra Tomas M, García-Gutierrez V, Magro Mazo E, Hernández-Boluda JC, Segura A, Raya JM, Navas Elorza B, Osorio S. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain. Ann Hematol. 2023 Feb;102(2):447-456.
Bobillo S, Wilson MR, Cwynarski K. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma. Curr Opin Oncol. 2023 Sep 1;35(5):382-388.
Marchetti M, Salmanton-García J, El-Ashwah S, Verga L, Itri F, Ráčil Z, Dávila-Valls J, Martín-Pérez S, Van Doesum J, Passamonti F, Abu-Zeinah G, Farina F, López-García A, Dragonetti G, Cattaneo C, Gomes Da Silva M, Bilgin YM, Žák P, Petzer V, Glenthøj A, Espigado I, Buquicchio C, Bonuomo V, Prezioso L, Meers S, Duarte R, Bergantim R, Jaksic O, Čolović N, Blennow O, Cernan M, Schönlein M, Samarkos M, Mitra ME, Magliano G, Maertens J, Ledoux MP, Jiménez M, Demirkan F, Collins GP, Cabirta A, Gräfe SK, Nordlander A, Wolf D, Arellano E, Cordoba R, Hanakova M, Zambrotta GPM, Nunes Rodrigues R, Limberti G, Marchesi F, Cornely OA, Pagano L. Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry. Ther Adv Hematol. 2023 Mar 11;14:20406207231154706.
Palomba ML, Ghione P, Patel AR, Nahas M, Beygi S, Hatswell AJ, Kanters S, Limbrick-Oldfield EH, Wade SW, Ray MD, Owen J, Neelapu SS, Gribben J, Radford J, Bobillo S. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Expert Rev Anticancer Ther. 2023 Feb;23(2):199-206.
Carlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, Yeh SP, Bouabdallah K, Cartron G, Kim WS, Cordoba R, Koh Y, Re A, Alves D, Chamuleau M, Le Gouill S, López-Guillermo A, Moreira I, van der Poel MWM, Abbadessa G, Meng R, Ji R, Lépine L, Saleem R, Ribrag V. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. Hematol Oncol. 2023 Feb;41(1):108-119.
Bastos-Oreiro M, Gutierrez A, Iacoboni G, López Corral L, Reguera JL, Abrisqueta P, Delgado J, Terol MJ, Hernani R, Martínez N, Ortíz V, Bailen R, Gomez-Centurión I, Caballero A, Sanz J, Guerra Domínguez L, Luzardo H, Mussetti A, Jiménez-Ubieto A, Sancho JM, Sureda A, Pérez A, Barba P, Kwon M, Martín García-Sancho A. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Transplant Cell Ther. 2023 Dec;29(12):747.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, Karras N, McGuirk J, Hamerschlak N, López-Torija I, Sanz G, Valcarcel D, Horwitz ME. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy. Transplant Cell Ther. 2023 Aug;29(8):517.e1-517.e12.
Gazeau N, Liang EC, Wu QV, Voutsinas JM, Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R, Ortiz-Maldonado V, Martínez-Cibrian N, Martinez AP, Maziarz RT, Williamson S, Nemecek ER, Shadman M, Cowan AJ, Green DJ, Kimble E, Hirayama AV, Maloney DG, Turtle CJ, Gauthier J. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2023 Jul;29(7):430-437.
de la Rubia J, González B, Cruz-Jentoft AJ, Iglesias L, Jarque I, Persona EP, Lluch R, Marrero C, Zudaire M, Gironella M, Hernández-Rivas JÁ, Arnan M, Olivier C, Encinas C, Soler JA, Payer ÁR, Casado A, Fernández P, Vilanova D, Bonanad S. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study. J Geriatr Oncol. 2023 Jan;14(1):101401.
Olivera P, Velásquez-Escandón C, Campoy D, Flores K, Canals T, Johansson E, Herranz MJ, Martínez L, Cerezo-Manchado JJ, Salinas R. Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231180865.
Cerezo Manchado JJ, Iturbe Hernández T, Martínez Pacheco MDC, Gil Ortega I, Campoy D, Canals Pernas T, Martinez Serra L, Flores Aparco KJ, Velasquez Escandon CA, García de Guadiana-Romualdo L, Martinez Frances A, Olivera P. Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231208440.
Medina I, Carpio C, Ruiz-Camps I, Albasanz-Puig A, Lopez-Godino O, Esperalba J, Beas F, Sanchez-Salinas M, Iacoboni G, Barba P. Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma. Immunotherapy. 2023 Nov;15(16):1369-1374.
Haque T, Cadenas FL, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, Brunner AM, Chromik J, Morillo D, Patel MR, Falantes J, Leitch HA, Germing U, Preis M, Lenox L, Lauring J, Brown RJ, Kalota A, Mehta J, Pastore F, Gu J, Mistry P, Valcárcel D. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leuk Res. 2023 Nov;134:107390.
Fernandez-Sojo J, Valdivia E, Esquirol A, Portos JM, Rovira M, Suarez M, Diaz-de-Heredia C, Uría ML, Ortí G, Ferra C, Mussetti A, Paviglianiti A, Marsal J, Badell I, Lozano M, Gomez D, Azqueta C, Martorell L, Rubio N, Garcia-Buendia A, Villa J, Carreras E, Querol S. Development of an in-house bone marrow collection kit: The Catalan bone marrow transplantation group experience. Vox Sang. 2023 Sep;118(9):783-789.
Velasco P, Bautista F, Rubio A, Aguilar Y, Rives S, Dapena JL, Pérez A, Ramirez M, Saiz-Ladera C, Izquierdo E, Escudero A, Camós M, Vega-García N, Ortega M, Hidalgo-Gómez G, Palacio C, Menéndez P, Bueno C, Montero J, Romecín PA, Zazo S, Alvarez F, Parras J, Ortega-Sabater C, Chulián S, Rosa M, Cirillo D, García E, García J, Manzano-Muñoz A, Minguela A, Fuster JL. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP). Front Pediatr. 2023 Sep 20;11:1269560.
Bravo J, Baltasar Tello P, González Garcia E, Ríos Herranz E, Páyer AR, Terol Castera MJ, Champ D, Medina Perez A, Gironella M, Fernández Zarzoso M, Forés R, Delgado J, Garcia-Marco JA; GABRIELL Study Group/Investigators. Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study. Leuk Lymphoma. 2023 May;64(5):913-926.
Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D; ERASME study group. Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice. Leuk Lymphoma. 2023 Mar;64(3):679-690.
Cerezo Manchado JJ, Iturbe Hernández T, Martínez Pacheco MDC, Gil Ortega I, Campoy D, Canals Pernas T, Martínez Serra L, Flores Aparco KJ, Velásquez Escandón CA, Martínez Francés A, Olivera P. Impact of atrial fibrillation and anticoagulation on the risk of death, thromboembolic disease and bleeding in patients with COVID-19: the ACO-VID Registry. Curr Med Res Opin. 2023 Jun;39(6):811-817.
López-Jaime FJ, Benítez O, Díaz Jordán BL, Montaño A, Coll J, Quintana París L, Gómez-Del Castillo Solano MDC. Expert opinion paper on the treatment of hemophilia a with emicizumab. Hematology. 2023 Dec;28(1):2166334.
Benítez-Hidalgo O, Bosch Schips M, Juárez Giménez JC, Gironella M. Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre. Hematology. 2023 Dec;28(1):2242656.
Pardos-Gea J, Cortina V, Marques-Soares JR, Martínez F, Gironella M. Severe bleeding diathesis as onset of light-chain amyloidosis: combined excessive fibrinolysis and acquired von Willebrand disease in a young patient. Blood Coagul Fibrinolysis. 2023 Jan 1;34(1):79-81.
Ligero M, Simó M, Carpio C, Iacoboni G, Balaguer-Montero M, Navarro V, Sánchez-Salinas MA, Bobillo S, Marín-Niebla A, Iraola-Truchuelo J, Abrisqueta P, Sala-Llonch R, Bosch F, Perez-Lopez R, Barba P. PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma. EJHaem. 2023 Sep 11;4(4):1081-1088.
Benítez Hidalgo O, Martinez Garcia MF, Corrrales Insa I, Fernández-Caballero M, Ramírez Orihuela L, Cortina Giner V, Comes Fernández N, Juarez Gimenez JC. VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohort. EJHaem. 2023 Mar 9;4(2):476-482.
Mallo M, Tuechler H, Arenillas L, Raynaud S, Cluzeau T, Shih LY, Tung-Liang C, Ganster C, Shirneshan K, Haase D, Mascaró M, Palomo L, Cervera J, Such E, Trim N, Jeffries S, Ridgway E, Marconi G, Martinelli G, Solé F. Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype. EJHaem. 2023 Feb 7;4(2):446-449.
Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, Boix J, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, González M, Zenz T, Crespo M, Bosch F. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763-5773.
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774-784.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606-3610.
Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Dec 15;387(24):2220-2231.
Jiménez I, Tazón-Vega B, Abrisqueta P, Nieto JC, Bobillo S, Palacio-García C, Carabia J, Valdés-Mas R, Munuera M, Puigdefàbregas L, Parra G, Esteve-Codina A, Franco-Jarava C, Iacoboni G, Terol MJ, García-Marco JA, Crespo M, Bosch F. Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. Biomark Res. 2021 May 20;9(1):37.
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774-784. Blood Adv. First Edition 29 November 2021 (online prepublication).
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. Epub 2021 Dec 14.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. Epub 2021 Dec 14.

Olga Salamero, Pau Montesinos, Christophe Willekens, José Antonio Pérez-Simón, Arnaud Pigneux, Christian Récher, Rakesh Popat, Cecilia Carpio, César Molinero, Cristina Mascaró, Joaquim Vila, M Isabel Arévalo, Tamara Maes, Carlos Buesa, Francesc Bosch, Tim C P Somervaille. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology 2020 Dec 20; 38(36):4260-4273
Abrisqueta P, Bosch F. Venetoclax-obinutuzumab: harnessing complexity. Blood 2020 Mar 12; 135(11):788-789
Jiménez I, Carabia J, Bobillo S, Palacio C, Abrisqueta P, Pagès C, Nieto JC, Castellví J, Martínez-Ricarte F, Escoda L, Perla C, Céspedes Torrez DH, Boix J, Purroy N, Puigdefàbregas L, Seoane J, Bosch F, Crespo M. Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. J Neurooncol. 2020 Aug;149(1):13-25.
Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellvi J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane, J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. Epub ahead of print.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, WeiX, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. 2020 Mar 26;135(13):996-1007.
Muntañola A, Villacampa G, Hernández-Rivas JÁ, Alonso R, Mirás F, Osorio S, Baile M, Baltasar P, López Jiménez J, Hernandez-Rodriguez I, Valenciano S, Alfayate A, Gimeno E,Bárez A, Oliveira AC, Riaza R, Romero P, Delgado J, Yáñez L, Zabalza A, Torres A, Gómez-Roncero MI, Crespo M, Córdoba R, Mateos-Mazón JJ, Pérez S, Andreu R, Labrador J, Ruiz ME, Velasquez CA, Terol MJ, Santiago R, Vidal MJ, Campoy García F, Villalón L, Muiña BS, Soler JA, Seri C, Sánchez MJ, Cuesta A, Ramos R, Sánchez- Montalvá A, Ruiz-Camps I, González M, Abrisqueta P, Bosch F; of the GELLC (Grupo Español de Leucemia Linfática Crónica). Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. Exp Hematol Oncol. 2020 Dec 18;9(1):37.
Bosch F, Dalla-Favera R. Chronic Lymphocytic Leukaemia: From Genetics to Treatment. Nat Rev Clin Oncol. 16 (11), 684-701, Nov 2019.
Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot J-L, Tausch E, Trunzer K, Robson S, Gresko E, Böttcher S, Foà R, Stilgenbauer S, Leblond V. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia, 34 (2), 441-450. 2019.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.

Todas las publicaciones

Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, Boix J, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, González M, Zenz T, Crespo M, Bosch F. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763-5773.
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta-Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M, Fox L, Orti G, Barba P, Pumarola T, Cabirta A, Catalá E, Valentín M, Marín-Niebla A, Orfao A, González M, Campins M, Ruiz-Camps I, Valcárcel D, Bosch F, Hernández M, Crespo M, Esperalba J, Abrisqueta P. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2022 Feb 8;6(3):774-784.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022 Jun 28;6(12):3606-3610.
Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022 Dec 15;387(24):2220-2231.
Noelia Purroy; Júlia Carabia; Pau Abrisqueta; Leire Egia; Meritxell Aguiló; Cecilia Carpio; Carles Palacio; Marta Crespo; Francesc Bosch. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget. 2017 Jan 3;8(1):742-756
Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D. Donor Lymphocyte Infusions in AML and MDS:enhancing the Graft-versus-Leukemia effect. Experimental Hematology. 24/12/2016. [Epub ahead of print]
Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; tamatopoulos K; Espinet B. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016 Dec 6;7(49):80916-80924
Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic LymphocyticLeukemia. Advanced Therapies. 33(10), pp. 1814 – 1830. 03/10/2016.
González-Gascón Y Marín I; Hernández-Sánchez M; Rodríguez-Vicente AE; Sanzo C; Aventín A; Puiggros A; Collado R; Heras C; Muñoz C; Delgado J; Ortega M; González MT; Marugán I; de la Fuente I; Recio I; Bosch F; Espinet B; González M; Hernández-Rivas JM; Hernández JÁ;; On behalf of Grupo Español de Leucemia Linfática Crónica (GELLC); Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016 Jun;34(2):84-92
Bär C; Povedano JM; Serrano R; Benitez-Buelga C; Popkes M; Formentini I; Bobadilla M; Bosch F; Blasco MA. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. Blood. 127 – 14, pp. 1770 – 1779. 07/04/2016.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O’Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; , Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An European research initiative on CLL (ERIC) study. Leukemia. 2016 Apr;30(4):929-36.
Pons V; Olivera P; García-Consuegra R,; López-Andreoni L; Martín-Begué N; García A, Hidalgo J,; Bosch F; Santamaría A. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. J Thromb Thrombolysis. 2016 Apr;41(3):544-7
Hernández JÁ; Hernández-Sánchez M; Rodríguez-Vicente AE; Grossmann V; Collado R; Heras C; Puiggros A; Martín AÁ; Puig N; Benito R; Robledo C; Delgado J; González T; Queizán JA; Galende J; de la Fuente I; Martín-Núñez G; Alonso JM; Abrisqueta P; Luño E; Marugán I; González-Gascón I; Bosch F; Kohlmann A; González M; Espinet B; Hernández-Rivas JM. A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. PLoS One. 2015 Dec 2;10(11):e0143073.
Riveiro-Barciela M; Artaza G; Abrisqueta P; Bosch F; Buti M. Importance of hepatitis B virus screening in hematological patients. Gastroenterol Hepatol. 2015 Nov;38(9):563-4
Purroy N; Abrisqueta P; Carabia J; Carpio C; Palacio C; Bosch F; Crespo M. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015 Apr 10;6(10):7632-43.
Purroy N; Abrisqueta P; Carabia J; Carpio C; Calpe E; Palacio C; Castellví J; Crespo M; Bosch F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 28 – (10), pp. 1993 – 2004.
Maria Joao Baptista; Eva Calpe; Eva Fernández; Lluis Colomo; Teresa Marta Cardesa-Salzmann; Pau Abrisqueta; Francesc Bosch; Marta Crespo. Analysis of the IGHV region in Burkitt’s lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. Leuk Res. 2014 Apr;38(4):509-15
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014 Jan;20(1):66-72
Abrisqueta P; Villamor M; Terol MJ; González- Barca E; Ferrà C; Abella E; Delgado J; Garcia-Marco JA; Gonzalez Y; CarbonellF; Monzo E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013 Dec 5;122(24):3951-9.05/12/2013.
Calpe E; Purroy N; Carpio C; Abrisqueta P; Carabia J; Palacio C; Castellví J; Crespo M; Bosch F.ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation. PLoS One. 2013 Dec 3;8(12):e81221.
Puiggros A; DelgadoJ; Rodriguez- Vicente A; Collado R; Aventín A; Luño E; Luño E; Grau J; Hernandez JÁ; Marugán I; Ardanaz M; González T; Valiente A; Osma M; Calasanz MJ; Sanzo C; Carrió A; Ortega M; Santacruz R; Abrisqueta P; Abella E; Bosch F; Carbonell F; Solé F; Hernández JM; Espinet B. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. Br J Haematol. 2013 Oct;163(1):47-54
Mora D; Barba P; Castillo N; Aizpurua M; Rosellé E; Bosch F; Valcárcel D. Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report. Transpl Infect Dis. 2013 Jun;15(3):E107-10
Villamor N; Conde L; Martínez-Trillos A; Cazorla M; Navarro A; Beà S; López C; Colomer D; Pinyol M; Aymerich, M; Rozman M; Abrisqueta P; Baumann T; Delgado J; Giné E; González-Díaz M; Hernández JM; Colado E; Payer AR; Rayon C; Navarro B; José Terol M; Bosch F; Quesada V; Puente XS; López-Otín C; Jares P; Pereira A; Campo E; López-Guillermo A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013 Abr; 27(5): 1100 – 1106.
Baptista MJ, Muntanola A, Calpe E, Abrisqueta P, Salamero O, Fernandez E, Codony C, Gine E, Kalko SG, Crespo M, Bosch F. Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clin Cancer Res. 2012 Sep;18(21):5924-33.
Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymph. 2012 Mar;53(3):417-23.
Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3
Calpe E, Codony C, Baptista MJ, Abrisqueta P, Del Carpio C, Purroy N, Bosch F, Crespo M. ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011 Oct 20; 111(16): 4401-10- 2011.
Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, Marcos MÁ, Martínez MJ, Tudó G, Bosch F, Pahissa A, de Anta MT, Pumarola T. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis. 2010 Nov;68(3):214-9.
M Hallek*, K Fischer*, G Fingerle-Rowson, A M Fink, R Busch, J Mayer, M Hensel, G Hopfi nger, G Hess, U von Grünhagen, M Bergmann, J Catalano, P L Zinzani, F Caligaris-Cappio, J F Seymour, A Berrebi, U Jäger, B Cazin, M Trneny, A Westermann, C M Wendtner, B F Eichhorst, P Staib, A Bühler, D Winkler, T Zenz, S Böttcher, M Ritgen, M Mendila, M Kneba, H Döhner, S Stilgenbauer, International Group of investigators; German Chronic Lymphocityc Study Group, Collaborators: Hillmen P, Dighiero G, Bosch F, Brugiatelli M, Pigeot I. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74.
Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntañola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010 Sep; 95(9):1526-33.
Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymph. 2010 Jul;51(7):1225-32
Fernández de Larrea C, Martínez C, Gaya A, López-Guillermo A, Rovira M,Fernández-Avilés F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol. 2010 Jun;21(6):1211-6.
Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, Camacho F, Beà S, Hartmann E, Amador V, Hernández L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, López-Guillermo A, Jares P, Serrano S, Campo E. Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Res. 2010 Feb 15; 70(4):1408-18
Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 20;27(27):4578-84.
Abrisqueta P, Pereira A, Rozman C, Aymerich M, Giné E, Moreno C, Muntañola A,Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009 Sep 3;114(10):2044-50
Hartmann E, Fernàndez V, Moreno V, Valls J, Hernández L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster E, Müller-Hermelink HK, Ott G, Rosenwald A, Campo E. Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. J Clin Oncol. 2008 Oct 20;26(30):4966-72.
Enjuanes A, Benavente Y, Bosch F, Martín-Guerrero I, Colomer D, Pérez-Alvarez S, Reina O, Ardanaz MT, Jares P, García-Orad A, Pujana MA, Montserrat E, de Sanjosé S, Campo E. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res. 2008 Dec 15;68(24):10178-86.
Giné E, Crespo M, Muntañola A, Calpe E, Baptista MJ, Villamor N, Montserrat E, Bosch F. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. Haematologica. 2008 Jan; 93(1):75-82.
Fernàndez V, Jares P, Salaverria I, Giné E, Beà S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat E, Campo E. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica. 2008 Jan; 93(1):132-6.
Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1; 14(1):155-61.
Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008 Jan;19(1):135-41.
Ferrer A, Salaverria I, Bosch F, Villamor N, Rozman M, Bea S, Gine E, Lopez-Guillermo A, Campo E, Montserrat E. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007; 109:2473-80
Muntañola A, Bosch F, Arguis P, Arellano-Rodrigo E, Ayuso C, Gine E, Crespo M, Abrisqueta P, Moreno C, Cobo F, Lopez-Guillermo A, Montserrat E. Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic. Leukemia. J Clin Oncol 2007; 25:1576-80
Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose JM, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood. 2007;109(11):4599-606.
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, Belhoul L, Stella S, Stavroyianni N, Crespo M, Hadzidimitriou A, Sutton L, Bosch F, Laoutaris N, Anagnostopoulos A, Montserrat E, Fassas A, Dighiero G, Caligaris-Cappio F, Merle-Beral H, Ghia P, Davi F. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109:259-70
Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol. 2006 Oct;17(10):1539-45
Bosch F, Muntanola A, Gine E, Carrio A, Villamor N, Moreno C, Crespo M, Montserrat E. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70:214-7
Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A, Campo E, Bosch F, Montserrat E. Clinical significance of minimal residual disease, as assessed by different techniques, after stem-cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-9
Marce S, Balague O, Colomo L, Martinez A, Holler S, Villamor N, Bosch F, Ott G, Rosenwald A, Leoni L, Esteller M, Fraga MF, Montserrat E, Colomer D, Campo E. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy. Clin Cancer Res 2006; 12:3754-61.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood; 2006; 107:1276-83
Crespo M, Villamor N, Gine E, Muntanola A, Colomer D, Marafioti T, Jones M, Camos M, Campo E, Montserrat E, Bosch F. ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006 12:726-34.
Plancarte F, Lopez-Guillermo A, Arenillas L, Montoto S, Gine E, Muntanola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 2006 76:58-63
Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J, Bosch F, López-Guillermo A, Campo E, Sierra J, Montserrat E. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23(15):3433-8
López-Guillermo A, Colomo L, Jiménez L, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E. Diffuse large B-cell lymphoma: clinicobiological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23(12):2797-804
Hernández L, Beà S, Pinyol M, Ott G, Katzenberger T, Rosenwald A, Bosch F, López-Guillermo A, Delabie J, Colomer D, Montserrat E, Campo E. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005; 65: 2199-206.
Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, Tort F, Bosch F, López-Guillermo A, Colomer D, Montserrat E, Campo E. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507-13.
Ferrer A, Marcé S, Bellosillo B, Villamor N, Bosch F, López-Guillermo A, Espinet B, Solé F, Montserrat E, campo E, Colomer D. Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.Oncogene 2004; 23: 8941-9.
Montoto S, López-Guillermo A, Altés A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Campo E, Sierra J, Montserrat E. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004; 15: 1484-9.
Montagut C, Bosch F, Villela L, Rosinol L, Blade J. Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. Leuk Lymph.2004 Aug;45(8):1711-2
Tort F, Camacho E, Bosch F, Lee Harris N, Montserrat E, Campo E. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004; 89:314-9
Martínez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D. Nuclear survivin expresion in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164:501-510
Bosch F, Villamor N. ZAP-70 expression in chronic lymphocytic leukemia: a new parameter for an old disease. Haematologica 2003; 88:724-26.
Perea G, Altés A, Montoto S, López-Guillermo A, Bosch F, Jiménez M, Esteve J, Domingo E, Ribera JM, Pedro C, Martino R, Briones J, Sureda A, Brunet S, Sierra J, Montserrat E. International and Italian prognostic indices in follicular lymphoma. Haematologica 2003; 88: 700-4.
Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé BS, López-Guillermo A, Campo E, Monserrat E. ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75. (first and corresponding author)
Montoto S, Rozman M, Rosinol L, Nadal E, Gine E, Aymerich M, Ferrer A, Esteve J, Bosch F, Lopez-Guillermo A, Blade J, Montserrat E. Malignant transformation in IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003 Apr;30(2):178-81
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hemerlink KH, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, Feb; 3:185-197.
Colomo L, López-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84
Montoto S, López-Guillermo A, Colomer D, Esteve J, Bosch F, Ferrer A, Villamor N, Moreno C, Campo E, Montserrat E. Incidence and clinical significance of bcl-2/IgH rearrangement in follicular lymphoma. Leuk Lymph 2003; 44: 71-6.
Bosch F, Ferrer A, López-Guillermo A, Giné E, Bellosillo B, Villamor N, Colomer D, Cobo F, Perales M, Esteve J, Altés A, Besalduch J, Ribera JM, Montserrat, for the GELCAB (Grup per l’Estudi dels Limfomes de Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976-84.
Beà S, López-Guillermo A, Ribas M, Pinyol M, Carrió A, Soler F, Bosch F, Colomer D, Miró R, Montserrat E, Campo E. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large cell lymphoma (Richter’s syndrome). Am J Pathol 2002; 161: 957-68.
Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, Montserrat E, Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100: 1810-6.
Giné E, Bosch F, Villamor N, Rozman M, Colomer D, López-Guillermo A, Montserrat E. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia / small lymphocytic lymphoma: a frequent association? Leukemia 2002; 16: 1454-9.
Cobo F, Martínez A, Pinyol M, Hernández L, Gómez M, Beà S, Esteve J, Rozman M, Bosch F, López-Guillermo A, Montserrat E, Campo E. Multiple cell cycle regulator alterations in Richter’s transformation of chronic lymphocytic leukemia. Leukemia 2002; 16: 1028-34.
Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F, Giné E, Nadal E, Aymerich M, Rozman M, Montserrat E. Interleukin 6 and tumor necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 117:387-9
Montoto S, López-Guillermo A, Ferrer A, Camós M, Álvarez-Larrán A, Bosch F, Bladé J, Cervantes F, Esteve J, Cobo F, Colomer D, Campo E, Montserrat E. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol 2002; 13: 523-30.
Gallart T, Benito C, Reverter JC, Bosch F, Blay M, Tassies D, Vigorito E, Cervera R, Font J, Gomis R, Campo E, Vives J. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br J Haematol 2002;116:875-86
Camacho E, Hernández L, Hernández S, Tort F, Bellosillo B, Beà S, Bosch F, Montserrat E, Cardesa A, Fernández PL, Campo E. ATM gene inactivation in mantle cell lymphoma mainly occur by truncating and missense mutations involving the PI-3 kinase domain. Blood 2002 99: 238-244.
Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, Binet JL, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-4258
Marti RM, Campo E, Bosch F, Palou J, Estrach T. Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. J Cutan Pathol 2001 28:256-64.
Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, Guccione E, Qu X, Chien M, Murty VV, Gaidano G, Inghirami G, Zhang P, Fischer S, Kalachikov SM, Russo J, Edelman I, Efstratiadis A, Dalla-Favera R. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97:2098-104
Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001; 91: 1557-62.
Sanz-Vaqué, Ll, Colomer D, Bosch F, López-Guillermo A, Dreyling MH, Ott G, Montserrat E, Campo E. Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica 2001; 86: 181-6..
Migliazza A, Cayanis E, Bosch F, et al. Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. Curr Top Microbiol Immunol. 2000;252:275-84.
Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Bladé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E. Hybrid chemotherapy C-MOPP/ABV as first line treatment in advanced stage Hodgkin’s disease. Cancer 2000; 88: 2142-8.
Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, Campo E. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia. 1999; 13:2087-93.
Cobo F, Hernández S, Hernández L, Pinyol M, Bosch F, Esteve J, López-Guillermo A, Palacín A, Raffeld M, Montserrat E, Jaffe ES, Campo E. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma ocurring in an HIV-seronegative patient. J Pathol 1999; 189: 288-93.
Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Campo E, Montserrat E. Expression of beta-integrin adhesion molecules in non-Hodgkin’s lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999; 17: 1869-75.
Beà S, Ribas M, Hernández JM, Bosch F, Pinyol M, Hernández L, García JL, Flores T, González M, López-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miró R, Campo E. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphomas are associated with blastoid variants. Blood 1999; 93: 4365-74.
Geisler C, Hansen MM, Yeap BY, Wiernik P, Binet JL, Chastang C, Dighiero G, Travade P, Jaksic B, Brugiatelli M, Kimby E, Catovsky D, Hamblin T, Richards S, Bosch F, Fontanillas M, Montserrat E, Alison R, Clarke M, Duong H, Elphinstone P, Evans V, Godwin J, Gray R, Greaves E, Hicks C, James S, Mead G, Peto R, Richards S, Wheatley K. Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials. J Natl Cancer Inst. 1999 May 19;91(10):861-8.
Ferrer A, López-Guillermo A, Bosch F, Montoto S, Hernández Boluda JC, Camós M, Miquél R, Campo E, Montserrat E. Linfomas del tejido linfoide asociado a mucosas (MALT) de localización extragástrica: análisis de 14 casos. Med Clin (Barc) 1999; 112: 577-80.
Espinet B, Sole F, Woessner S, Bosch F, Florensa L, Campo E, Costa D,Lloveras E, Vila RM, Besses C, Montserrat E, Sans-Sabrafen J. Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet 1999; 111:92-8.
Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998; 158: 1889-93
López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, Fernández de Sevilla A, Bosch F, Montserrat E. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998; 9: 849-55.
Sanz L, López-Guillermo A, Martínez C, Bosch F, Esteve J, Cobo F, Montoto S, Perales M, Bladé J, Cervantes F, Campo E, Montserrat E. Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. Eur J Haematol 1998; 61: 59-64.
Terol MJ, López-Guillermo A, Bosch F, Villamor N, Cid MC, Rozman C, Campo E, Montserrat E. Expression of the adhesion molecule ICAM-1 (CD54) in non-Hodgkin’s lymphoma. Relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998; 16: 35-40.
Targarona EM, Espert JJ, Balague C, Sugranes G, Ayuso C, Lomena F, Bosch F, Trias M. Residual splenic function after laparoscopic splenectomy: a clinical concern. Arch Surg 1998; 133:56-60.
Montserrat E, Bosch F, Rozman C. B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol. 1997;8 1:93-101
Montserrat E, Bosch F, Rozman C. Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectivas. J Intern Med 242: 63-67 740, 1997
Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-75.
Esteve J, Villamor N, Colomer D, Bosch F, López-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E. Hematopoietic stem-cell transplantation for chronic lymphocytic leukemia. Report of 12 patients from a single institution. Ann Oncol 1998; 9: 167-72.
Rozman C, Bosch F, Montserrat E Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997 Jun;11(6):775-8.
Cervantes F, López-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996; 57: 286-91.
Briones J, Montserrat E, Urbano-Ispizua A, Esteve J, Colomer D, López-Guillermo A, Bosch F, Hadjieu E, Rozman C. Tratamiento con fludarabina de neoplasias linfoides de bajo grado de malignidad resistenctes al tratamiento o en recaída. Med Clin 1996; 107: 86-9.
Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernández PL, Sánchez-Beato M, Soler F, Pérez-Losada A, Nayach I, Mallofré C, Piris MA, Montserrat E, Cardesa A. Expression of retinoblastoma gene product (pRb) in mantle cell lymphoma. Correlation with Cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol, 1996; 148(5): 1591-1600.
Montserrat E, López-Lorenzo JL, Manso F, Martín A, Prieto E, Arias-Sampedro J, Fernández MN, Oyarzábal FJ, Odriozola J, Alcalà A, García-Conde J, Conde E, Guardia R, Bosch F. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish Group Experience. Leukemia and Lymphoma, 1996; 21:467-472.
Montserrat E, Villamor N, Reverter JC, Brugues RM, Tassies D, Bosch F, Aguilar JL, Vives-Corrons JL, Rozman M, Rozman C. Bone marrow assessment in B-cell chronic lymphocytic leukemia: aspirate or biopsy?. A comparative study in 258 patients. Br J Haematol, 1996; 93(1): 111-116.
Hernández L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffold M. p53 gene mutations and protein overexpression are associated with agressive variants of mantle cell lymphomas. Blood, 1996; 87(8): 3351-3359.
Esteve J, Cervantes F, Bosch F, Cobo F, Montserrat E, Rozman C. Tratamiento con interferón alfa del síndrome hipereosinofílico idiopático resistente a la terapéutica convencional. Med Clin, 1996; 106: 304-306.
Montserrat E, Bosch F, López-Guillermo A, Graus F, Terol MJ, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14: 941-4.
Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, Piris MA, DeWolf-Peeters C, Jaffe ES, Rozman C, Montserrat E, Cardesa A. Increased expression of the PRAD-1/CYCLIN D1 gene in hairy cell leukemia. Br J Haematol 1995; 91(4): 1025-1030.
Esteve J, López-Guillermo A, Martínez-Francés A, Bosch F, Terol MJ, Campo E, Montserrat E, Rozman C. Presenting features, natural history, and prognostic factors in localized non-Hodgkin’s lymphomas: analysis of 117 cases from a single institution. Eur J Haematol 1995; 55: 217-222.
Fraga M, Lloret E, Sánchez-Verde L, Orrade JL, Campo E, Bosch F, Piris MA. Mucosal mantle (centrocytic) lymphomas. Histopathology, 1995; 26: 413-422.
Martínez – Francés A; López – Guillermo A; Esteve J; Bosch F; Terol MJ; Montserrat E. Characteristics of patients with low grade malignant lymphoma and long survival. Sangre (Barc). 1995 Feb;40(1):53-7.
Bosch F, Jares P, Campo E, López-Guillermo A, Villamor N, Tassies D, Piris MA, Jaffe ES, Montserrat E, Rozman C, Cardesa A. PRAD-1/Cyclin D1 overexpression in lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84(8): 2726-2732.
Bladé J, López-Guillermo A, Bosch F, Cervantes F, Reverter JC, Montserrat E, Rozman C. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117-21.
López-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol MJ, Marín P, Reverter JC, Bladé J, Cervantes F, Sierra J, Rovira M, Nomdedeu B, Urbano-Ispizua A, Carreras E, Campo E, Rozman C. Low-grade lymphomas: clinical and prognostic studies in a series of 143 patients from a single institution.Leuk Lymph 1994; 15: 159-65.
Jares P, Fernández PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, Cardesa A. PRAD1/Cyclin D1 gene amplification correlates with mRNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994; 54: 4813-4817.
López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343-8.
Campo E, Miquel R, Jares P, Bosch F, Juan M, Leone A, Vives J, Cardesa A, Yagüe J. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorrectal carcinomas. Cancer 1994; 73: 2913-2921.
Villamor N, Marín P, Aymerich M, Arriols R, Rovira M, Bosch F, Vilella R, Rozman C, Vives-Corrons JL. Diagnóstico de la hemoglobinuria paroxística nocturna mediante el análisis citofluorimétrico de moléculas unidas a membrana por grupos glucosilfosfatidilinositol. Med Clin 1994; 102: 481-484.
Cervantes F, Urbano-Ispízua A, Pujades A, Bosch F, Vives-Corrons JL, Montserrat E, Rozman C. Análisis molecular en la leucemia mieloide crónica cromosoma Filadelfia negativa: estudio de seis casos.Med Clin 1992; 99: 286-288
Sierra J, Grañena A, Bosch F, Carreras E, Martí JM, Urbano-Ispízua A, Rovira M, Rozman C. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. Hematol Oncol 1992; 10: 301-309.